-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background and purpose: Emphysema mediastinal (PTM) is the abnormal presence of air or gas in the mediastinum
.
Spontaneous PTM is rare, occurring in approximately 1 in 33,000 hospitalized patients
Emphysema mediastinal (PTM) is the abnormal presence of air or gas in the mediastinal cavity
RESULTS: During the study period, 377 cases of mediastinal emphysema were identified among 58,484 inpatients with COVID-19 in 53 hospitals, representing an incidence rate of 0.
64%
.
The overall 120-day mortality rate for COVID-19 mediastinal emphysema was 195/377 (51.
Table 1 Binary logistic regression model for predicting 120-day mortality from mediastinal air volume (all patients eligible for mechanical ventilation, n=315)
.
In univariate analysis, all variables significantly associated with mortality were entered stepwise backward into the model
Table 1 Binary logistic regression model for predicting 120-day mortality from mediastinal air volume (all patients eligible for mechanical ventilation, n=315)
Figure 1 Sankey Plot of maximal respiratory support for all patients 4 hours before and 4 hours after diagnosis of mediastinal emphysema (n = 374)
.
The mean fractions of inspired oxygen (FiO2) and positive end-expiratory pressure (PEEP) at these levels of support are shown in the table below
Figure 1 Sankey Plot of maximal respiratory support for all patients 4 hours before and 4 hours after diagnosis of mediastinal emphysema (n = 374)
Figure 2.
Alluvial plot depicting the trajectories of 93 patients eligible for mechanical ventilation with continuous positive airway pressure (CPAP) at the time of diagnosis of mediastinal emphysema
.
At diagnosis, there were no statistically significant differences in age, maximal fractional inspiratory oxygen (FiO2), or maximal positive end-expiratory pressure (PEEP) in patients who subsequently continued CPAP versus those who subsequently switched to oxygen or high-flow nasal oxygen (HFNO) difference
Figure 2.
Figure 3 Mediastinal emphysema coexisting with subcutaneous emphysema, tension pneumothorax, and use of intercostal thoracic drainage tubes (n = 377)
.
Bilateral pneumothorax is caused by pneumothorax on both sides of the chest in the same patientFigure 3 Mediastinal emphysema coexisting with subcutaneous emphysema, tension pneumothorax, and use of intercostal thoracic drainage tubes (n = 377)
Mediastinal emphysema may be a hallmark of severe COVID-19 pneumonia
.
Most patients with confirmed mediastinal emphysema are not on mechanical ventilation at the time of diagnosis
.
Original source: Melhorn J, Achaiah A, Conway FM, et al.
Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the United Kingdom (POETIC) survey.
Eur Respir J 2022 Feb 10
Leave a comment here